# EDGAR Filing Document

**Accession Number:** 0001401017
**File Stem:** 0001628280-25-030969
**Filing Date:** 2025-6
**Character Count:** 8905
**Document Hash:** 329b1f83f3f5a073e07585455e50d89f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-030969.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001628280-25-030969

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250610

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Schaeffer Orlov S Nicole
- **CENTRAL INDEX KEY:** 0001401017

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30739
- **FILM NUMBER:** 251042954

**MAIL ADDRESS:**
- **STREET 1:** INSMED INCORPORATED
- **STREET 2:** 700 US-206
- **CITY:** BRIDGEWATER
- **STATE:** NJ
- **ZIP:** 08807
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INSMED Inc
- **CENTRAL INDEX KEY:** 0001104506
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 541972729
- **STATE OF INCORPORATION:** VA
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 700 US HIGHWAY 202/206
- **CITY:** BRIDGEWATER
- **STATE:** NJ
- **ZIP:** 08807
- **BUSINESS PHONE:** 908-977-9900

**MAIL ADDRESS:**
- **STREET 1:** 700 US HIGHWAY 202/206
- **CITY:** BRIDGEWATER
- **STATE:** NJ
- **ZIP:** 08807

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INSMED INC
- **DATE OF NAME CHANGE:** 20000128

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Schaeffer Orlov S Nicole<br><sub>(Last) (First) (Middle)</sub><br>700 US HIGHWAY 202/206<br><sub>(Street)</sub><br>BRIDGEWATER, NJ 08807<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-10 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief People Strategy Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>INSMED Inc [ INSM ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-06-10 |  | M<sup>(1)</sup> |  | 38300 | A | $17.16 | 156879 | D |  |
| Common Stock | 2025-06-10 |  | S<sup>(1)</sup> |  | 38300 | D | $88.64 | 118579 | D |  |
| Common Stock | 2025-06-11 |  | M<sup>(2)</sup> |  | 70000 | A | $13.91 | 188579 | D |  |
| Common Stock | 2025-06-11 |  | S<sup>(2)</sup> |  | 35072 | D | 91.68<sup>(3)</sup> | 153507 | D |  |
| Common Stock | 2025-06-11 |  | S<sup>(2)</sup> |  | 18319 | D | 92.73<sup>(4)</sup> | 135188 | D |  |
| Common Stock | 2025-06-11 |  | S<sup>(2)</sup> |  | 10781 | D | 93.48<sup>(5)</sup> | 124407 | D |  |
| Common Stock | 2025-06-11 |  | S<sup>(2)</sup> |  | 34500 | D | 95.49<sup>(6)</sup> | 89907 | D |  |
| Common Stock | 2025-06-11 |  | S<sup>(2)</sup> |  | 500 | D | 96.02<sup>(7)</sup> | 89407 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $17.16 | 2025-06-10 |  | M<sup>(1)</sup> |  |  | 38300 | <sup>(8)</sup> | 2027-05-17 | Common Stock | 38300 | $0 | 0 | D |  |
| Stock Option (right to buy) | $13.91 | 2025-06-11 |  | M<sup>(2)</sup> |  |  | 70000 | <sup>(8)</sup> | 2029-01-03 | Common Stock | 70000 | $0 | 87290 | D |  |

---

### Footnotes:

(1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 15, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

(2) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 26, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

(3) This is the weighted average sales price representing 35,072 shares sold at prices ranging from $91.18 to $92.17 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

(4) This is the weighted average sales price representing 18,319 shares sold at prices ranging from $92.20 to $93.19 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

(5) This is the weighted average sales price representing 10,781 shares sold at prices ranging from $93.20 to $93.77 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

(6) This is the weighted average sales price representing 34,500 shares sold at prices ranging from $95.00 to $95.99 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

(7) This is the weighted average sales price representing 500 shares sold at prices ranging from $96.00 to $96.04 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

(8) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.

**Signature:** /s/ S. Nicole Schaeffer, by Michael A. Smith as Attorney-in-fact  
**Date:** 2025-06-12

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**